[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344941-105":3,"doc-detail-344941-en":81,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-significance-of-blood-based-multicancer-detection-in-circulating-tumor-dna-five-year-outcomes-analysis","Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis","","A multicancer early detection (MCED) test based on circulating tumor DNA (ctDNA) was assessed for prognostic value using the third Circulating Cell-free Genome Atlas validation substudy with 5-year follow-up. Overall survival was compared across cancer signal detected (CSD) versus no CSD (NCSD) groups and benchmarked against expected survival from SEER matched for clinical factors. Detected cancers showed long-term survival similar to expectations, suggesting clinically significant findings without added overdiagnosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-significance-of-blood-based-multicancer-detection-in-circulating-tumor-dna-five-year-outcomes-analysis/344941/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-significance-of-blood-based-multicancer-detection-in-circulating-tumor-dna-five-year-outcomes-analysis/344941.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of evaluating the MCED test in CCGA3 with 5-year follow-up?","Question",{"text":63,"@type":64},"To determine the prognostic significance of cancer signal detection by a ctDNA-based MCED test in the third CCGA validation substudy using updated statistics and longer follow-up.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were overall survival outcomes compared between CSD and NCSD groups?",{"text":68,"@type":64},"Observed overall survival was stratified by MCED result (CSD vs NCSD) and compared with expected survival from SEER data matched to age, sex, cancer type, and stage.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the five-year results indicate about survival for CSD cancers, especially in early stages?",{"text":72,"@type":64},"CSD cancers had long-term survival similar to expectations, even for early-stage disease, indicating early-stage detected cancers were unlikely to be more micrometastatic and lethal than cancers found by conventional methods.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344941,1790153523,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":33,"preview_urls":98},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Original Reports | Diagnostics  \nPrognostic Signiﬁcance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis  \nCharles Swanton, MD, PhD1  ; Alan Bryce, MD2  ; Allen L. Cohn, MD3; Matthew Margolis, MS4  ; Earl Hubbell, PhD4  ; April Sagan, PhD4  ; Oliver Venn, PhD4; and Michael Seiden, MD, PhD5  \nDOI [https://doi.org/10.1200/PO-25-00725](https://doi.org/10.1200/PO-25-00725)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | A multicancer early detection (MCED) test was developed and validated in the case-control Circulating Cell-free Genome Atlas (CCGA) study ([ClinicalTrials.gov](ClinicalTrials.gov)[ ](ClinicalTrials.gov)[identi](identi)ﬁ[er:](er:) NCT02889978) . Previous analysis of the second (cross-validation) CCGA substudy identiﬁed prognostic value of cancer signal detection by theMCED test with 3-year follow-up. Here, we evaluated the prognostic value of a cancer signal detected (CSD) result in the third (validation) CCGA substudy (CCGA3) using an updated statistical methodology with 5-year follow-up. |\n| METHODS | CCGA3 participants with conﬁrmed cancer were followed for up to 5 years; overall survival was stratiﬁed by MCED test result (CSD or no CSD [NCSD]) . Observed survival was compared with the expected survival of a reference population calculated from Surveillance, Epidemiology, and End Results data matched to clinical characteristics (age, sex, cancer type, and stage) in each signal detection group. |\n| RESULTS | Of 2,513 participants with stageable, invasive cancer, 792 (31.5%) died and 1,683 (67.0%) were conﬁrmed alive at follow-up, with 38 (1.5%) lost to follow-up. CSD rates were higher in participants who died during follow-up compared with those alive (85% v 34%). Overall observed survival versus expected survival was similar for CSD (43% observed v 40% expected) and NCSD (88% observed v 81% expected) groups. For NCSD, hazard ratios (HRs) were more favorable (\u003C1) relative to the matched reference population at all stages (P \u003C .0001); for CSD, HRs were \u003C1 at stages III to IV (P \u003C .0001) and @1 at stages I to II (P > .4) . |\n| CONCLUSION | CSD cancers had long-term survival similar to expectations, even in early stages, indicating that CSD early-stage cancers are unlikely to be more micrometastatic and lethal than cancers detected by conventional means. The MCED test was likely to ﬁnd clinically signiﬁcant cancers without contributing to overdiagnosis. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted January 29, 2026 Published March 12, 2026  \nJCO Precis Oncol 10:e2500725 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nMulti-cancer early detection (MCED) tests are an emerging screening technology that uses next-generation sequencing to detect cancer signals within blood analytes such as circulating tumor DNA (ctDNA), ie, fragments of genomic DNA shed into the bloodstream by tumor cells.1 MCED tests can screen for multiple cancer types simultaneously, including those without recommended screening and low-incidence cancer types for which single-cancer screening programs would be costly or impractical, allowing for the detection of cancers that would otherwise likely only present through symptoms at late stages.2-4 These attributes enable the diagnosis of cancers at earlier stages, when treatment is more  \neffective, and thus contribute to the potential mortality beneﬁt of population-level MCED screening programs.5,6  \nThe case-control Circulating Cell-free Genome Atlas (CCGA) study ([ClinicalTrials.gov](ClinicalTrials.gov) identiﬁer: NCT02889978) was designed to develop and assess the performance of an MCED test that detects cancer-associated methylation patterns inctDNA.7,8 The MCED test uses targeted methylation sequencing of ctDNA from plasma and machine learning classiﬁers to identify a cancer signal shared across many different cancer types. The classiﬁer was designed to have high (≥99.5%","cbCairGsEt97OxJ6","https://ap.wps.com/l/cbCairGsEt97OxJ6","pdf",1972911,13,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What is the purpose of evaluating the MCED test in CCGA3 with 5-year follow-up?\",\"answer\":\"To determine the prognostic significance of cancer signal detection by a ctDNA-based MCED test in the third CCGA validation substudy using updated statistics and longer follow-up.\"},{\"question\":\"How were overall survival outcomes compared between CSD and NCSD groups?\",\"answer\":\"Observed overall survival was stratified by MCED result (CSD vs NCSD) and compared with expected survival from SEER data matched to age, sex, cancer type, and stage.\"},{\"question\":\"What did the five-year results indicate about survival for CSD cancers, especially in early stages?\",\"answer\":\"CSD cancers had long-term survival similar to expectations, even for early-stage disease, indicating early-stage detected cancers were unlikely to be more micrometastatic and lethal than cancers found by conventional methods.\"}]","Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis | PDF",1790055856,33,[99,103,107,111],{"page_no":22,"url":100,"width":101,"height":102},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1da68aebe955d266b96911c194147fba.webp",983,1315,{"page_no":26,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35257dcc84390f6288e3a64478d8479f.webp",982,1314,{"page_no":30,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf0941ba5833fa9951fd53709501fe20.webp",981,1312,{"page_no":33,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9087ce2c72a2866ba12f5ed6623b0ae9.webp",980,1311,{"code":4,"msg":82,"data":116},[117,121,125,129,134,139,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":130,"slug":162},19,"General","general"]